%PDF-1.4
%
45 0 obj
<>
endobj
42 0 obj
<>
endobj
96 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T11:54:43Z
2024-03-29T03:51:21-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T03:51:21-07:00
application/pdf
Heather
2001-984.oct02
uuid:eb10baa1-1dd1-11b2-0a00-5b0827fd5800
uuid:eb10baa3-1dd1-11b2-0a00-6a0000000000
endstream
endobj
31 0 obj
<>
endobj
32 0 obj
<>
endobj
46 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
9 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
110 0 obj
[114 0 R]
endobj
111 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.3307 Tw 10 0 0 10 54 358.1616 Tm
(compliance advantage over the normal release capsule.)Tj
0.0806 Tw 0 -1.2 TD
(Multiple dose regimens are undesirable in elderly patients,)Tj
0.0417 Tw T*
[(as they are usually taking several dif)17.8 (ferent drugs on a daily)]TJ
0.1501 Tw T*
(basis. In these situations, even when compliance is good,)Tj
-0.00011 Tc 0.02499 Tw T*
(dosing at proper and regular intervals is rare.)Tj
0 Tc 0.0675 Tw 1.2 -1.2 Td
[(In conclusion, OD tramadol tablets are at least as ef)17.8 (fec-)]TJ
0.05991 Tw -1.2 -1.2 Td
(tive and well tolerated as a currently marketed short acting)Tj
-0.00529 Tw T*
[(tramadol formulation in the management of OA)-189.7 (pain, and in)]TJ
0.0833 Tw T*
[(addition, they of)17.8 (fer a reduced dosing regimen that is espe-)]TJ
0.02499 Tw T*
[(cially valuable in the elderly)64.9 (.)]TJ
/TT1 1 Tf
-0.00011 Tc 0 Tw 26.4 29.1 Td
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
0 Tc 0.03281 Tw 8 0 0 8 318 531.1616 Tm
(The authors thank Napp Pharmaceuticals Ltd., Cambridge, for preparation)Tj
-0.0211 Tw 0 -1.25 TD
(of the randomization schedule and the Statwood Partnership for their sta\
tis-)Tj
0.0668 Tw T*
[(tical analyses. )17.8 (The authors also thank the following for their participation)]TJ
0.0881 Tw T*
[(as investigators in this study: L.M. )54.9 (Adler)39.8 (, D.M. )54.9 (Allin, I.W)91.8 (. Bayman, N.J.)]TJ
0.04761 Tw T*
[(Bird, B. Bodalia, H. Bowen-Perkins, J. Chapman, )54.8 (A. Choudree, )17.7 (W)91.8 (. Clark,)]TJ
-0.00011 Tc 0.0515 Tw T*
[(C. Davis, M. Free, N.B. Gostick, G.I. Hackett, J.J. Hamill, )54.9 (A.H.N. Ko, R.)]TJ
0 Tc 0.24409 Tw T*
[(Lal-Sarin, C. Langdon, B.L. Lightstone, R.S. Lloyd, R. Maini, R.D.P)110.8 (.)]TJ
0.07629 Tw T*
[(Newland, )54.9 (A. Niven, N.L. Pinheiro, R.J. Pool, U.B.N. Rau, G.W)91.8 (. Roberts,)]TJ
0.17731 Tw T*
[(D. Rodgers, C. Solomon, P)110.8 (.C. Stott, D. Sweeney)65 (, )54.9 (A. )17.8 (T)69.8 (oman, R. )17.8 (V)111.1 (adas,)]TJ
-0.0269 Tw T*
[(A.R.J. W)79.8 (all, )-17.8 (and )37.2 (A.D. W)79.8 (eaver)54.9 (. The )-17.8 (authors )-17.8 (also )-17.8 (thank W)91.8 (. W)39.8 (ilkinson )-17.7 (for )-17.7 (her)]TJ
0.02499 Tw T*
(help with the preparation of this manuscript.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 10 0 0 10 318 407.1616 Tm
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 325 397.1616 Tm
[(1.)-875 (Roth SH. Ef)17.8 (ficacy and safety of tramadol HCl in breakthrough)]TJ
1.675 -1.25 Td
(musculoskeletal pain attributed to osteoarthritis. J Rheumatol)Tj
0 Tw T*
(1998;25:1358-63.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Bird HA, Hill J, Stratford ME, Fenn GC, )17.7 (W)39.7 (r)-0.1 (ight )17.7 (V)129.1 (.)-0.1 ( )54.8 (A)-219.9 (double-blind)]TJ
0 Tc 1.675 -1.25 Td
[(cross-over study comparing the analgesic ef)17.8 (ficacy of tramadol with)]TJ
T*
(pentazocine in patients with osteoarthritis. J Drug Dev Clin Pract)Tj
0 Tw T*
(1995;7:181-8.)Tj
0.0249 Tw -1.675 -1.25 Td
[(3.)-875 (Jensen EM, Ginsber)17.8 (g F)79.8 (. )17.7 (T)34.9 (ramadol versus dextropropoxyphene in)]TJ
1.675 -1.25 Td
[(the treatment of osteoarthritis. )54.9 (A)-219.8 (short term double-blind study)64.9 (.)]TJ
T*
[(Drug Invest 1994;8:21)36.9 (1-8.)]TJ
-1.675 -1.25 Td
[(4.)-875 (T)69.8 (odd KH, Funk JP)110.8 (. )17.7 (The minimum clinically important dif)17.8 (ference in)]TJ
1.675 -1.25 Td
[(physician-assigned visual analog pain scores. )54.8 (Acad Emer)17.8 (g Med)]TJ
0 Tw T*
(1996;3:142-5.)Tj
0.0249 Tw -1.675 -1.25 Td
[(5.)-875 (Dalgin PH. Use of tramadol in chronic pain. Clin Geriatr)]TJ
0 Tw 1.675 -1.25 Td
(1995;3:17-30.)Tj
0.02499 Tw -1.675 -1.25 Td
[(6.)-875 (Katz )17.8 (W)110.8 (A. Pharmacology and clinical experience with tramadol in)]TJ
1.675 -1.25 Td
(osteoarthritis. Drugs 1996;52 Suppl 3:39-47.)Tj
ET
0 0 0 0 scn
424 777 133 -27 re
f*
/CS0 CS 0 0 0 1 SCN
0.5 w
55 387.25 m
296.5 387.25 l
S
Q
Q
q
53 720 504 -169 re
W* n
q
/Fm0 Do
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT2 1 Tf
-0.00011 Tc 0.0251 Tw 8 0 0 8 55 594.5293 Tm
[(Figur)36.8 (e 3.)]TJ
/TT0 1 Tf
0 Tc 3.9668 0 Td
[(T)34.9 (ime to use of escape medication after the morning dose. NR: normal relea\
se.)]TJ
/TT2 1 Tf
-3.998 -6.8125 Td
[(T)92 (able 3.)]TJ
/TT0 1 Tf
3.4858 0 Td
(Incidence of adverse events. )Tj
-0.00011 Tc -3.4858 -2.5 Td
[(Adverse Event)-4085.6 (OD )17.7 (T)34.8 (ramadol \(%\))-2805.2 (Normal Release )]TJ
20.5623 -1.25 Td
[(T)34.8 (ramadol \(%\))]TJ
0 Tc -20.5623 -2.5 Td
(Six most commonly reported adverse events)Tj
-0.00011 Tc 0 Tw 1.4167 -1.25 Td
[(Nausea)-8828.5 (36)-8687.6 (36)]TJ
0 Tc 0 -1.25 TD
[(Constipation)-6659.8 (23)-8687.5 (31)]TJ
-0.00011 Tc T*
[(Drowsiness)-7105.9 (15)-8687.6 (24)]TJ
T*
[(Dizziness)-7884 (20)-8687.6 (17)]TJ
0 Tc T*
[(V)129.1 (omiting)-8066.5 (19)-8687.5 (18)]TJ
T*
[(Headache)-7829.7 (18)-8687.5 (15)]TJ
0.0249 Tw -1.4167 -1.25 Td
[(No statistically significant treatment dif)17.8 (ference for these adverse events.)]TJ
-0.00011 Tc 0 -1.85 TD
[(GI related)-9137.9 (62)-8687.6 (65)]TJ
0 -1.25 TD
[(CNS related)-8247.8 (48)-8687.6 (52)]TJ
ET
/CS0 CS 0 0 0 1 SCN
0.5 w
54.75 533 m
294.25 533 l
54.75 502.5 m
294.25 502.5 l
S
0.125 w
53.76 415.06 m
293.76 415.06 l
S
0 0 0 0 scn
428 770 130 -25 re
f*
1 w
54 54 m
558 54 l
S
BT
0 0 0 1 scn
/TT2 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Adler)110.7 (, et al: T)54.8 (ramadol in OA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2199)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 57.5 407.5 -10.84 re
f*
0.5 w
102.25 57.5 407.5 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
24 0 obj
<>stream
H;
0^-&n> bD"J`$@Cy@/!=hpVQ%e1*FDcqPĜBv.CK0 Ho
endstream
endobj
23 0 obj
<1.3<>>>
endobj
21 0 obj
<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
20 0 obj
<>stream
HpT6Lj`Jb@50
%@
iy!V<(8AyUD*`hAR !PI
ND( {e7C
&o&;;g7ߝoY1c1c1c1c**ׅ'rkazN"DaZvo.F }wɮ1K)CnρA\`Z hQz< 00wO6E1fCEx
hSi`dϐYc1lB(5$TyĚ_*v*@?g>GN95{ c>] cƻc^b+BMRŕ[S~].IP2^NBֻ%8p5E{\/'~Wwo?c1